RecruitingNot ApplicableNCT07431840

Immune Defense Protein Impact On Respiratory Immune Outcomes

A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Impact of IDP® Supplement on Respiratory Immune Health Outcomes During Cold and Flu Season in Older Individuals

Sponsor

Quantec Ltd

Enrollment

300 participants

Start Date

Dec 5, 2025

Study Type

INTERVENTIONAL

Conditions

Upper respiratory Disease Influenza Viral Upper Respiratory Infection

Summary

The primary goal of this study is to observe the impact of the IDP® Supplement on the duration and severity of upper respiratory symptoms in older individuals during the cold and flu season. Secondary aims include observing the product's effect on rescue medication use, quality of life, and overall tolerability. This is conducted as a consumer-driven, decentralized observational clinical research study in adults aged 60 or older, using self-reported measures and questionnaires completed at home via the Chloe App.

Eligibility

Min Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying IDP 200mg Dose, Immune Defense Protein 50mg Dose, and others for people with influenza, upper respiratory disease, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 60 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTImmune Defense Protein 50mg Dose

IDP dose of 50mg

DIETARY_SUPPLEMENTIDP 200mg Dose

IDP dose of 200mg

DIETARY_SUPPLEMENTMatching Placebo

Matching Placebo

Locations(1)

People Science, Inc.

Los Angeles, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07431840

Related Trials

Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients

NCT047125391 location

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Safety and Efficacy of Onradivir Tablets in Participants Aged 12 to 17 Years With Uncomplicated Influenza A.

NCT072295471 location